What are cytoreductive surgery and HIPEC?
Cytoreductive surgery (CRS) is a major operation to remove all visible cancer from the peritoneum, the thin lining of the abdomen, and from the organs it covers. HIPEC stands for hyperthermic intraperitoneal chemotherapy. It means bathing the inside of the abdomen with heated chemotherapy for a set time during the same operation, once the visible tumour has been removed.
The two are usually combined and often described together as CRS and HIPEC, or sometimes informally as the “Sugarbaker procedure”, after the surgeon who helped develop it. The aim is to remove every visible tumour deposit with surgery, and then use the heated chemotherapy to reach tiny cancer cells that cannot be seen.
CRS and HIPEC is a long and demanding operation offered only at specialist peritoneal centres. For carefully chosen people with cancer that has spread within the abdomen but nowhere else, it can give long-term control and, for some cancers, a chance of cure.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Major surgery combined with heated chemotherapy inside the abdomen |
| Main uses | Pseudomyxoma peritonei, peritoneal mesothelioma, selected colorectal and ovarian cancers with peritoneal spread |
| Anaesthetic | General anaesthetic, usually with an epidural |
| Length of operation | Often 6-12 hours |
| HIPEC time | Usually 30-90 minutes, depending on the drug |
| Hospital stay | About 1-3 weeks, often including a short stay in intensive care |
| Recovery | Usually 2-3 months before feeling close to normal |
| Main risks | Bleeding, infection, bowel leaks, blood clots, prolonged recovery |
2. How it works
Why the peritoneum is a special case
Some cancers spread by shedding cells into the abdominal cavity, where they settle on the peritoneal surfaces. Chemotherapy given into a vein reaches these surface deposits poorly, because the peritoneum has a limited blood supply. Placing chemotherapy directly into the abdomen allows much higher drug levels to reach the cancer cells while less drug enters the bloodstream.
The role of each part
| Component | What it does |
|---|---|
| Peritonectomy | Stripping away diseased areas of the abdominal lining |
| Organ removal | Removing affected organs or parts of them, such as the omentum, spleen, gallbladder, part of the bowel, ovaries or womb |
| Heat | Warming the chemotherapy to about 41-43 C makes cancer cells more sensitive and helps the drug penetrate tissue |
| Intraperitoneal chemotherapy | Delivers high drug levels to the surfaces where microscopic cancer may remain |
The Peritoneal Cancer Index
Surgeons score how much cancer is present using the Peritoneal Cancer Index (PCI). The abdomen is divided into 13 regions, and each is scored from 0 to 3 according to the size of the largest deposit, giving a total from 0 to 39. A lower score generally means a better chance of complete removal and a better outcome. A review of the principles of treatment emphasised that results are best when CRS and HIPEC are performed at a low PCI and when complete cytoreduction is achieved (Sugarbaker, 2015).
3. Who it is for
Conditions treated
| Condition | Role of CRS and HIPEC |
|---|---|
| Pseudomyxoma peritonei | Standard treatment when the disease can be removed |
| Appendiceal neoplasms | Mucinous and other appendix tumours that have spread to the peritoneum |
| Peritoneal mesothelioma | Main treatment for suitable people with disease limited to the abdomen |
| Colorectal adenocarcinoma | Complete cytoreduction is key; the added value of HIPEC is debated |
| Epithelial ovarian cancer | HIPEC during interval surgery after chemotherapy in selected women |
| High-grade serous ovarian carcinoma | As above, in specialist settings |
| Gastric adenocarcinoma | Limited peritoneal spread in selected people, often within trials |
| Desmoplastic small round cell tumour | Sometimes used in specialist centres alongside chemotherapy and radiotherapy |
Who may be suitable
| Factor | Typical requirement |
|---|---|
| Spread | Cancer limited to the abdomen, with no distant spread such as to the lungs |
| Amount of disease | Low enough that all visible tumour can be removed |
| Fitness | Good general health to withstand a long operation |
| Response to chemotherapy | For some cancers, the disease should be stable or responding |
| Nutrition | Adequate nutritional state, or improved before surgery |
Who is usually not suitable
| Situation | Reason |
|---|---|
| Spread outside the abdomen | Surgery cannot remove all cancer |
| Very extensive disease involving the small bowel | Complete removal may be impossible without losing too much bowel |
| Poor fitness or major heart or lung disease | High risk from the operation |
| Rapidly growing cancer on chemotherapy | Benefit is unlikely |
4. Before treatment
| Step | Why it is done |
|---|---|
| CT, MRI and sometimes PET scans | Estimate the extent of disease |
| Tumour markers | CEA, CA125, CA19-9 or others, depending on the cancer |
| Diagnostic laparoscopy | Keyhole look inside the abdomen to measure disease before committing to a large operation |
| Fitness testing | Heart and lung tests, sometimes a cardiopulmonary exercise test |
| Prehabilitation | Exercise, nutrition and stopping smoking to prepare for surgery |
| Stoma counselling | If part of the bowel may need to be brought out as a stoma |
| Multidisciplinary review | Surgeons, oncologists and radiologists agree the plan |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Anaesthetic | General anaesthetic and usually an epidural for pain relief |
| 2. Opening the abdomen | A long midline incision is made from below the breastbone to the pubic bone |
| 3. Assessment | The surgeon scores the PCI and decides if complete cytoreduction is possible |
| 4. Cytoreduction | Tumour deposits, affected lining and organs are removed; this can take many hours |
| 5. HIPEC | Tubes are placed and heated chemotherapy is circulated through the abdomen by a pump, for about 30-90 minutes |
| 6. Draining and washing | The chemotherapy is drained and the abdomen is rinsed |
| 7. Reconnection | Bowel ends are joined, or a stoma is formed |
| 8. Closure | The abdomen is closed, often with drains in place |
| 9. Intensive care or high-dependency unit | Close monitoring for the first one to several days |
| 10. Ward recovery | Gradual return to eating, walking and independence |
Open and closed techniques
In the open method, the abdomen is kept open and the surgeon gently moves the fluid by hand so it reaches every surface. In the closed method, the abdomen is temporarily closed while the fluid circulates. Both are used, and centres choose based on experience.
Drugs commonly used
| Drug | Typical setting |
|---|---|
| Mitomycin C | Pseudomyxoma peritonei, appendix and colorectal cancer |
| Cisplatin | Ovarian cancer and mesothelioma, sometimes with doxorubicin |
| Oxaliplatin | Colorectal cancer in some centres, though its use has fallen |
6. Side effects and risks
CRS and HIPEC is one of the largest operations in cancer surgery, and complications are common.
| Risk | Notes |
|---|---|
| Pain | Managed with an epidural and other pain relief |
| Slow return of bowel function | Feeding through a vein or tube may be needed for a time |
| Anastomotic leak or bowel perforation | A leak where the bowel was joined; may need further surgery |
| Infection | Wound, chest or abdominal infection |
| Bleeding | May need transfusion or return to theatre |
| Blood clots | Prevented with injections and stockings |
| Low blood counts | From absorbed chemotherapy |
| Kidney problems | Particularly with cisplatin |
| Fluid collections | May need drainage |
| Stoma | Temporary or permanent in some people |
| Death | A small risk at experienced centres |
Evidence on complications
In the PRODIGE 7 trial, serious complications at 30 days were similar with and without oxaliplatin HIPEC, but by 60 days they were more frequent in the HIPEC group (Quenet et al., 2021).
7. Results and outlook
| Study | Main finding |
|---|---|
| OVHIPEC-1, stage III ovarian cancer (245 women) | Adding cisplatin HIPEC to interval surgery after chemotherapy lengthened median survival from 33.9 to 45.7 months, with similar rates of severe side effects (van Driel et al., 2018) |
| PRODIGE 7, colorectal peritoneal metastases (265 people) | After complete cytoreduction, adding 30 minutes of oxaliplatin HIPEC did not improve survival; median survival was about 41 months in both groups (Quenet et al., 2021) |
| Pseudomyxoma peritonei consensus | Expert societies strongly recommend CRS and HIPEC over simple debulking; observational studies report around 80% of people alive at five years (Kusamura et al., 2025) |
Making sense of PRODIGE 7
PRODIGE 7 showed that people with colorectal peritoneal metastases who had complete cytoreduction lived much longer than older figures would suggest, but it could not show that the short oxaliplatin HIPEC itself added benefit. As a result, many centres now focus on complete surgery for colorectal cancer, and some use different drugs or longer HIPEC within trials. The completeness of cytoreduction remains the single most important factor across all cancers.
8. Recovery and aftercare
Recovery timeline
| Period | What to expect |
|---|---|
| Days 1-3 | Intensive or high-dependency care; drains and tubes in place |
| Days 3-10 | Gradual return to drinking and eating; walking with help |
| Weeks 1-3 | Discharge home when eating and moving well |
| Weeks 3-12 | Tiredness, reduced appetite and weight loss slowly improve |
| Months 3-6 | Many people return to work or normal activities |
Practical tips
- Walk a little more each day to rebuild strength and reduce clot risk
- Eat small, frequent meals; a dietitian can help if weight loss continues
- Avoid heavy lifting for at least 6-8 weeks to protect the wound
- Learn stoma care before leaving hospital if you have one
- Report fever, worsening pain, vomiting or wound redness to your team
Further treatment
Depending on the cancer, more chemotherapy may be given after recovery. For ovarian cancer, this is a standard part of the plan. For pseudomyxoma peritonei and mesothelioma, follow-up with scans and tumour markers may be all that is needed.
Follow-up
| Check | Typical timing |
|---|---|
| Clinic review | Every 3-6 months at first |
| Tumour markers | At each visit |
| CT or MRI scans | Every 6-12 months, more often at first |
| Long-term follow-up | Often for 10 years or more for pseudomyxoma peritonei |
Emotional recovery
Recovering from such a large operation can be slow and frustrating, and many people feel low or anxious in the first months. Specialist peritoneal centres usually have nurse specialists and support groups. Talking with others who have been through CRS and HIPEC can help set realistic expectations.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Systemic chemotherapy alone | When surgery cannot remove all disease, or as the main treatment for many cancers |
| Debulking surgery without HIPEC | To relieve symptoms when complete removal is not possible |
| PIPAC (pressurised intraperitoneal aerosol chemotherapy) | Keyhole delivery of chemotherapy spray for people unsuitable for CRS, mainly in trials |
| Immunotherapy or targeted therapy | Depending on the cancer’s features; see immune checkpoint inhibitors |
| Clinical trials | Different HIPEC drugs or techniques |
| Supportive and palliative care | Symptom control, including drainage of fluid |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is HIPEC the same as normal chemotherapy? | No; it is a single treatment given into the abdomen during surgery |
| Will I lose my hair? | Usually not from HIPEC alone |
| Will I need a stoma? | Sometimes, depending on which parts of the bowel are removed |
| How long is the operation? | Often 6-12 hours, sometimes longer |
| Why is it only done at certain hospitals? | Results are better at centres with large experience |
| Can it be repeated? | Sometimes, for recurrence of slow-growing disease such as pseudomyxoma |
| Will I be cured? | It depends on the cancer; cure is possible for some, especially pseudomyxoma and mesothelioma |
11. Questions to ask your care team
- What is my Peritoneal Cancer Index, and can all disease be removed?
- What are my chances of a complete cytoreduction?
- Which organs may need to be removed?
- Which drug will be used for HIPEC, and why?
- How many of these operations does your centre perform each year?
- What complications are most likely for me?
- Will I need chemotherapy before or after surgery?
Resources
- Kusamura, S. et al. (2025) ‘Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of pseudomyxoma peritonei: a GRADE approach for evidence evaluation and recommendation’, Journal of Surgical Oncology, 132(5), pp. 810-816.
- Quenet, F. et al. (2021) ‘Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial’, The Lancet Oncology, 22(2), pp. 256-266.
- Sugarbaker, P.H. (2015) ‘Management of peritoneal metastases – basic concepts’, Journal of BUON, 20(Suppl 1), pp. S2-S11.
- van Driel, W.J. et al. (2018) ‘Hyperthermic intraperitoneal chemotherapy in ovarian cancer’, New England Journal of Medicine, 378(3), pp. 230-240.
- National Cancer Institute (2026) Colon Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Ovarian Epithelial, Fallopian, and Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.